Candriam S.C.A. Tricida, Inc. Transaction History

Candriam S.C.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 19, 2020	SELL	$8.56 - $26.93 $1.64 Million - $5.16 Million	-191,500 Closed	0 $0
Q2 2020 Jul 23, 2020	BUY	$21.21 - $31.55 $159,075 - $236,625	7,500 Added 4.08%	191,500 $5.26 Million
Q4 2019 Jan 21, 2020	SELL	$29.6 - $43.71 $592,000 - $874,200	-20,000 Reduced 9.8%	184,000 $7,000
Q3 2019 Oct 21, 2019	BUY	$29.87 - $42.22 $5.4 Million - $7.64 Million	180,899 Added 783.08%	204,000 $6,000
Q2 2019 Aug 01, 2019	BUY	$31.16 - $39.46 $719,827 - $911,565	23,101 New	23,101 $908,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.